{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:39:59Z","timestamp":1784677199291,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"crossref","award":["20180550768"],"award-info":[{"award-number":["20180550768"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13760-020-01336-z","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:02:54Z","timestamp":1585612974000},"page":"889-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis"],"prefix":"10.1007","volume":"121","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"issue":"8","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","volume":"9","author":"M Lai","year":"2010","unstructured":"Lai M et al (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9(8):776\u2013785","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"1336_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.10.005","volume":"265","author":"YW Shin","year":"2013","unstructured":"Shin YW et al (2013) VGKC-complex\/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265(1\u20132):75\u201381","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/WCO.0000000000000444","volume":"30","author":"AEM Bastiaansen","year":"2017","unstructured":"Bastiaansen AEM, van Sonderen A, Titulaer MJ (2017) Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies). Curr Opin Neurol 30(3):302\u2013309","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404","journal-title":"Lancet Neurol"},{"issue":"4","key":"1336_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/epi.13671","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS et al (2017) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531\u2013542","journal-title":"Epilepsia"},{"issue":"10","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.autrev.2016.07.018","volume":"15","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen A et al (2016) From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev 15(10):970\u2013974","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","volume":"30","author":"M Spatola","year":"2017","unstructured":"Spatola M, Dalmau J (2017) Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol 30(3):345\u2013353","journal-title":"Curr Opin Neurol"},{"key":"1336_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yebeh.2015.12.041","volume":"56","author":"L Gao","year":"2016","unstructured":"Gao L et al (2016) Clinical characterization of autoimmune LGI1 antibody limbic encephalitis. Epilepsy Behav 56:165\u2013169","journal-title":"Epilepsy Behav"},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.yebeh.2018.08.019","volume":"88","author":"LH Li","year":"2018","unstructured":"Li LH et al (2018) Clinical and electrographic characteristics of seizures in LGI1-antibody encephalitis. Epilepsy Behav 88:277\u2013282","journal-title":"Epilepsy Behav"},{"issue":"19","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","volume":"92","author":"M de Bruijn","year":"2019","unstructured":"de Bruijn M et al (2019) Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92(19):e2185\u2013e2196","journal-title":"Neurology"},{"key":"1336_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.yebeh.2018.10.038","volume":"94","author":"W Zhang","year":"2019","unstructured":"Zhang W et al (2019) Seizure characteristics, treatment, and outcome in autoimmune synaptic encephalitis: a long-term study. Epilepsy Behav 94:198\u2013203","journal-title":"Epilepsy Behav"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.yebeh.2017.08.011","volume":"77","author":"C Chen","year":"2017","unstructured":"Chen C et al (2017) Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis. Epilepsy Behav 77:90\u201395","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ana.22307","volume":"69","author":"SR Irani","year":"2011","unstructured":"Irani SR et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69(5):892\u2013900","journal-title":"Ann Neurol"},{"issue":"15","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/WNL.0b013e3182152808","volume":"76","author":"DM Andrade","year":"2011","unstructured":"Andrade DM et al (2011) Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 76(15):1355\u20131357","journal-title":"Neurology"},{"issue":"Pt 10","key":"1336_CR15","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/brain\/awt212","volume":"136","author":"SR Irani","year":"2013","unstructured":"Irani SR et al (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136(Pt 10):3151\u20133162","journal-title":"Brain"},{"issue":"2","key":"1336_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/brain\/awx323","volume":"141","author":"J Thompson","year":"2018","unstructured":"Thompson J et al (2018) The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141(2):348\u2013356","journal-title":"Brain"},{"issue":"1","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ana.22470","volume":"70","author":"P Striano","year":"2011","unstructured":"Striano P (2011) Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol 70(1):179\u2013180","journal-title":"Ann Neurol"},{"issue":"6","key":"1336_CR18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s00415-013-6946-7","volume":"260","author":"F Boesebeck","year":"2013","unstructured":"Boesebeck F et al (2013) Faciobrachial dystonic seizures arise from cortico-subcortical abnormal brain areas. J Neurol 260(6):1684\u20131686","journal-title":"J Neurol"},{"issue":"3","key":"1336_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.spen.2014.08.002","volume":"21","author":"DS Khurana","year":"2014","unstructured":"Khurana DS (2014) Focal epilepsies: immunologic and inflammatory mechanisms. Semin Pediatr Neurol 21(3):207\u2013213","journal-title":"Semin Pediatr Neurol"},{"issue":"8","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1073\/pnas.0914537107","volume":"107","author":"Y Fukata","year":"2010","unstructured":"Fukata Y et al (2010) Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA 107(8):3799\u20133804","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/brain\/aww012","volume":"139","author":"V Navarro","year":"2016","unstructured":"Navarro V et al (2016) Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 139(4):1079\u20131093","journal-title":"Brain"},{"issue":"14","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","volume":"87","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen A et al (2016) Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 87(14):1449\u20131456","journal-title":"Neurology"},{"key":"1336_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2147\/NDT.S136723","volume":"13","author":"M Wang","year":"2017","unstructured":"Wang M et al (2017) Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat 13:1589\u20131596","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1336_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","volume":"74","author":"C Finke","year":"2017","unstructured":"Finke C et al (2017) Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 74(1):50\u201359","journal-title":"JAMA Neurol"},{"issue":"6","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1212\/NXI.0000000000000161","volume":"2","author":"EP Flanagan","year":"2015","unstructured":"Flanagan EP et al (2015) Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2(6):e161","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"28","key":"1336_CR26","doi-asserted-by":"publisher","first-page":"e4244","DOI":"10.1097\/MD.0000000000004244","volume":"95","author":"Z Li","year":"2016","unstructured":"Li Z et al (2016) Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures. Medicine 95(28):e4244","journal-title":"Medicine"},{"issue":"8","key":"1336_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","volume":"87","author":"H Arino","year":"2016","unstructured":"Arino H et al (2016) Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 87(8):759\u2013765","journal-title":"Neurology"},{"key":"1336_CR28","doi-asserted-by":"crossref","first-page":"175628561772234","DOI":"10.1177\/1756285617722347","volume":"11","author":"YW Shin","year":"2018","unstructured":"Shin YW et al (2018) Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord 11:1756285617722347","journal-title":"Ther Adv Neurol Disord"},{"issue":"1\u20132","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jneuroim.2014.03.012","volume":"271","author":"JW Brown","year":"2014","unstructured":"Brown JW et al (2014) Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. J Neuroimmunol 271(1\u20132):66\u201368","journal-title":"J Neuroimmunol"},{"issue":"2","key":"1336_CR30","first-page":"91","volume":"50","author":"NbotCM Association","year":"2017","unstructured":"Association NbotCM (2017) Chinese experts consensus on the diagnosis and treatment of autoimmune encephalitis. Chin J Neurol 50(2):91\u201398","journal-title":"Chin J Neurol"},{"issue":"4","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1212\/NXI.0000000000000353","volume":"4","author":"AM Feyissa","year":"2017","unstructured":"Feyissa AM, Chiriboga ASL, Britton JW (2017) Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 4(4):e353","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01336-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01336-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01336-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T22:10:54Z","timestamp":1628374254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01336-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01336-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"4 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}